ENBREL (etanercept) is no longer covered on the Reformulary. Reformulary covers 2 preferred etanercept biosimilars that offer the same clinical value at a lower net cost to the plan. Both biosimilars, ERELZI and BRENZYS require Special Authorization.
Biosimilars are safe and clinically similar to the originator biologic, and have the potential to provide significant savings to you and your plan – this is essential to drug plan sustainability.
ENBREL is used to treat
Juvenile Idiopathic Arthritis